The European Bioanalysis Forum recommendation on establishing appropriate drug tolerance levels in antidrug antibody assays

The European Bioanalysis Forum, in collaboration with several key industry stakeholders, has recently led discussions that address international immunogenicity guidance documents, specifically the three tier approach for immunogenicity testing strategies, after more than 20 years of experience with biotherapeutics. As part of this, the strategy and methods used to assess drug tolerance across all immunogenicity assays are challenged, emphasizing that bioanalytical scientists need to consider the context-of-use of each assay. Here, recommendations for drug tolerance assessments, driven by strong scientific rationale and subject to reevaluation as needed, are provided. This includes carefully considering the drug and positive control concentrations considered to be appropriate and which tiers are most relevant for performing drug tolerance assessments.

Authors

Institutions

Publication Details

Journal
Bioanalysis
Published
2024-08-05
DOI
https://doi.org/10.1080/17576180.2024.2376950
Citations
6
Primary Topic
Biosimilars and Bioanalytical Methods
Type
article
Field-Weighted Citation Impact
1.44
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The European Bioanalysis Forum recommendation on establishing appropriate drug tolerance levels in antidrug antibody assays

Foka Venema, Philip Timmerman, Jean‐Christophe Genin, Arno Kromminga et al.
6 citations
Bioanalysis
Biosimilars and Bioanalytical Methods
1.44
article

The European Bioanalysis Forum recommendation on establishing appropriate drug tolerance levels in antidrug antibody assays

Foka Venema, Philip Timmerman, Jean‐Christophe Genin, Arno Kromminga, Morten Carlsen, Martin Rieger, Michaela Golob, Kyra J. Cowan, Joanne Goodman, Ortwin Van de Vyver, Lysie Champion, Heather Revell, Laura Geary, D. C. Dyer, R. L. Nelson
article en
6 citations

Abstract

The European Bioanalysis Forum, in collaboration with several key industry stakeholders, has recently led discussions that address international immunogenicity guidance documents, specifically the three tier approach for immunogenicity testing strategies, after more than 20 years of experience with biotherapeutics. As part of this, the strategy and methods used to assess drug tolerance across all immunogenicity assays are challenged, emphasizing that bioanalytical scientists need to consider the context-of-use of each assay. Here, recommendations for drug tolerance assessments, driven by strong scientific rationale and subject to reevaluation as needed, are provided. This includes carefully considering the drug and positive control concentrations considered to be appropriate and which tiers are most relevant for performing drug tolerance assessments.

BioanalysisVol. 16(17-18)
AstraZeneca (United Kingdom) (GB), Roche (Switzerland) (CH), MorphoSys (Germany) (DE), Merck KGaA, Darmstadt (Germany) (DE), Bioanalytica (Switzerland) (CH), Celerion (United States) (US), Sanofi (Belgium) (BE), BioNTech (Germany) (DE), Nuvisan (Germany) (DE), Leo Pharma (Denmark) (DK)
Good health and well-being
Openalex Percentile: Top 18%
Biosimilars and Bioanalytical Methods
1.44
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The European Bioanalysis Forum recommendation on establishing appropriate drug tolerance levels in antidrug antibody assays — Foka Venema, Philip Timmerman, et al. · Bioanalysis (2024) | TGRS Research Map | TGRS